PCSK9 Antagonists for LDL Cholesterol Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular conditions, particularly those related to LDL cholesterol levels, are limited in effectively managing hypercholesterolemia and coronary heart disease due to the role of PCSK9 in regulating LDL cholesterol levels, which is not adequately addressed by existing therapies.
Innovation Solution
Development of protein-specific antagonists, such as monoclonal antibodies, that selectively bind to PCSK9, inhibiting its function and thereby reducing LDL cholesterol levels and treating conditions like hypercholesterolemia and coronary heart disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to manage hypercholesterolemia, then treatment is provided, but LDL cholesterol levels are not effectively reduced due to PCSK9 regulation
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (PCSK9) that prevents effective LDL cholesterol reduction. By developing monoclonal antibodies that specifically bind to and inhibit PCSK9, the therapy removes the blocking factor that limits the effectiveness of existing cholesterol-lowering treatments, thereby enabling more effective LDL reduction.
Solution Approach 2:
The patent introduces monoclonal antibodies as intermediary molecules that mediate between the therapeutic goal (lowering LDL cholesterol) and the biological obstacle (PCSK9 regulation). These antibodies serve as mediators that specifically bind to PCSK9 and prevent it from interfering with LDL receptor function, thus enabling effective cholesterol management.
2Object-affected harmful factors
If PCSK9 function is not inhibited, then natural cholesterol regulation is maintained, but LDL cholesterol levels remain elevated causing cardiovascular conditions
Solution Approach 1:
The patent applies preliminary anti-action by administering monoclonal antibodies that preemptively bind to PCSK9 before it can exert its harmful effect of elevating LDL cholesterol levels. This preventive inhibition blocks the pathological mechanism in advance, preventing the development or progression of cardiovascular conditions associated with high LDL cholesterol.
3Quantity of substance
If monoclonal antibodies are developed to bind PCSK9, then LDL cholesterol levels are reduced, but treatment complexity increases
Solution Approach 1:
The patent uses naturally occurring monoclonal antibodies (or their engineered variants) as therapeutic agents, copying the body's own immune response mechanism. These antibodies are produced through biotechnological processes that replicate natural antibody structures and functions, providing a biologically compatible treatment that reduces LDL cholesterol through a mechanism that mimics natural immune regulation rather than introducing entirely artificial complex systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PCSK9-specific antagonists effectively counteract PCSK9-dependent inhibition of LDL uptake, leading to significant reductions in plasma LDL cholesterol levels and improved management of associated cardiovascular conditions.
Implementation Method 1
protein-specific antagonists, such as monoclonal antibodies, that selectively bind to PCSK9
Data Source
AI summary
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.